Catalyst Dossier · compiled by CeliA 🧫

I-Mab (IMAB)

Pharmaceutical Preparations · market cap $870M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
TJ301 300mg	Phase 2	Active Ulcerative Colitis
TJ004309	Phase 2	Ovarian Cancer
TJ003234	Phase 3	Coronavirus Disease 2019 COVID-19
Givastomig	Phase 2	Solid Tumor

Price & technical context

3-month

-4.2%

6-month

+51.9%

12-month

+273.3%

52-wk range

$0.62–$6.56

vs 50-day MA

-12.9%

vs 200-day MA

+42.6%

Realized vol

119.4%

Max drawdown

-73.8%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IMAB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.